Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Market Cap	2.02B
Revenue (ttm)	977.79M
Net Income (ttm)	-102.95M
Shares Out	76.92M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	0.19 (0.74%)
Ex-Dividend Date	Jul 24, 2025

Volume	1,000
Average Volume	97,993
Open	26.30
Previous Close	26.20
Day's Range	25.85 - 26.30
52-Week Range	23.50 - 36.35
Beta	0.45
RSI	74.42
Earnings Date	Mar 20, 2026

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxant...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1964
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1762

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.